These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 8137263)

  • 21. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.
    Lüttges J; Schlehe B; Menke MA; Vogel I; Henne-Bruns D; Klöppel G
    Cancer; 1999 Apr; 85(8):1703-10. PubMed ID: 10223563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
    Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster.
    Cerny WL; Mangold KA; Scarpelli DG
    Cancer Res; 1992 Aug; 52(16):4507-13. PubMed ID: 1643642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular genetics of malignant insulinoma.
    Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
    Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region.
    Sturm PD; Hruban RH; Ramsoekh TB; Noorduyn LA; Tytgat GN; Gouma DJ; Offerhaus GJ
    J Pathol; 1998 Nov; 186(3):247-53. PubMed ID: 10211112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
    Slebos RJ; Hoppin JA; Tolbert PE; Holly EA; Brock JW; Zhang RH; Bracci PM; Foley J; Stockton P; McGregor LM; Flake GP; Taylor JA
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1223-32. PubMed ID: 11097231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis.
    Löhr M; Müller P; Mora J; Brinkmann B; Ostwald C; Farré A; Lluis F; Adam U; Stubbe J; Plath F; Nizze H; Hopt UT; Barten M; Capellá G; Liebe S
    Gastrointest Endosc; 2001 Jun; 53(7):734-43. PubMed ID: 11375580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct sequencing analysis of exon 1 of the c-K-ras gene shows a low frequency of mutations in human pancreatic adenocarcinomas.
    Gonzalez-Cadavid NF; Zhou D; Battifora H; Bar-Eli M; Cline MJ
    Oncogene; 1989 Sep; 4(9):1137-40. PubMed ID: 2674856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 and RAS gene mutations in multiple myeloma.
    Portier M; Molès JP; Mazars GR; Jeanteur P; Bataille R; Klein B; Theillet C
    Oncogene; 1992 Dec; 7(12):2539-43. PubMed ID: 1461658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation.
    Yamaguchi Y; Watanabe H; Yrdiran S; Ohtsubo K; Motoo Y; Okai T; Sawabu N
    Clin Cancer Res; 1999 May; 5(5):1147-53. PubMed ID: 10353750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis.
    Nindl I; Gottschling M; Krawtchenko N; Lehmann MD; Röwert-Huber J; Eberle J; Stockfleth E; Forschner T
    Br J Dermatol; 2007 May; 156 Suppl 3():34-9. PubMed ID: 17488404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Frequency of K-ras mutation in biliary and pancreatic tumors].
    Roa JC; Anabalón L; Tapia O; Melo A; de Aretxabala X; Roa I
    Rev Med Chil; 2005 Dec; 133(12):1434-40. PubMed ID: 16446870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coamplification at lower denaturation temperature polymerase chain reaction enables selective identification of K-Ras mutations in formalin-fixed, paraffin-embedded tumor tissues without tumor-cell enrichment.
    Yu S; Xie L; Hou Z; Qian X; Yu L; Wei J; Ding Y; Liu B
    Hum Pathol; 2011 Sep; 42(9):1312-8. PubMed ID: 21406308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice.
    Reyes G; Villanueva A; García C; Sancho FJ; Piulats J; Lluís F; Capellá G
    Cancer Res; 1996 Dec; 56(24):5713-9. PubMed ID: 8971180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
    Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
    J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients.
    Uemura T; Hibi K; Kaneko T; Takeda S; Inoue S; Okochi O; Nagasaka T; Nakao A
    J Gastroenterol; 2004 Jan; 39(1):56-60. PubMed ID: 14767735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
    Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
    Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple detection of genetic alterations in tumors and stool.
    Rengucci C; Maiolo P; Saragoni L; Zoli W; Amadori D; Calistri D
    Clin Cancer Res; 2001 Mar; 7(3):590-3. PubMed ID: 11297253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer.
    Pellegata NS; Losekoot M; Fodde R; Pugliese V; Saccomanno S; Renault B; Bernini LF; Ranzani GN
    Anticancer Res; 1992; 12(5):1731-5. PubMed ID: 1444240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor.
    Hrasćan R; Pavelić K; Pavicić D; Krizanac S; Stajcer-Sittić V; Pecur L; Spaventi S; Klimpfinger M; Pavelić J
    Anticancer Res; 1996; 16(6B):3761-6. PubMed ID: 9042254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.